Keyphrases
Diabetes
100%
Randomized Clinical Trial
100%
Weight Loss
100%
Type 2 Diabetic Patients
100%
Liraglutide
100%
Placebo
73%
Type 2 Diabetes Mellitus (T2DM)
15%
Weight Management
10%
Liraglutide 3.0 Mg
10%
Sulfonylurea
5%
Comorbidity
5%
Physical Activity
5%
Placebo-controlled
5%
Overweight or Obesity
5%
Metformin
5%
Body Mass Index
5%
Inclusion Criteria
5%
Long-term Efficacy
5%
Pancreatitis
5%
Relative Change
5%
Once-daily
5%
Long-term Safety
5%
Gastrointestinal Diseases
5%
Effective Weight
5%
Thiazolidinediones
5%
Parallel Trials
5%
Glycated Hemoglobin Levels
5%
Oral Hypoglycemic Agents
5%
Importance Weights
5%
Immunology and Microbiology
Body Weight
100%
Physical Activity
100%
Body Mass
100%
Hemoglobin Blood Level
100%
Pancreatitis
100%
Comorbidity
100%
Glycosylated Hemoglobin
100%
Medicine and Dentistry
Patient with Type 2 Diabetes
100%
Randomized Clinical Trial
100%
Diabetes
100%
Liraglutide
100%
Placebo
71%
Maturity Onset Diabetes of the Young
14%
Weight Management
9%
Body Mass Index
4%
Physical Activity
4%
Group Trial
4%
Body Weight
4%
Pancreatitis
4%
Glycon
4%
Glycated Hemoglobin
4%
Gastrointestinal Disease
4%
Oral Antidiabetic Agent
4%
Thiazolidinedione
4%
Sulfonylurea
4%
Comorbidity
4%
Pharmacology, Toxicology and Pharmaceutical Science
Randomized Clinical Trial
100%
Liraglutide
100%
Non Insulin Dependent Diabetes Mellitus
100%
Placebo
71%
Group Trial
4%
Sulfonylurea
4%
Metformin
4%
Pancreatitis
4%
Glycosylated Hemoglobin
4%
Thiazolidinedione
4%
Oral Antidiabetic Agent
4%
Gastrointestinal Disease
4%
Comorbidity
4%